Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Definium Therapeutics, Inc.DFTX · Entity 3884 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Definium Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 24,289 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 4,666 · Balance 24,289 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.11 · Expires 2036-06-10 | Direct | 19,188 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Grant · Acquired 19,188 · Balance 19,188 F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date.
F2: The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
OPIANT PHARMACEUTICALS, INC.
Report date March 02, 2023 · Filed March 03, 2023
Section 16 reporting ended · disclosed 2023-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-02 transaction · row 5
4 source rows · reconciled sequenceRow 1 · 2023-03-02 · Disposition to issuer · Disposed 37,438 · Balance 37,901 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). Row 2 · 2023-03-02 · Disposition to issuer · Disposed 37,901 · Balance 0 F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement. Row 4 · 2023-03-02 · Grant · Acquired 6,667 · Balance 6,667 F3: 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer. Row 5 · 2023-03-02 · Disposition to issuer · Disposed 6,667 · Balance 0 F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement. |
| Common Stock par value $0.001SEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 3
1 source rowRow 3 · 2023-03-02 · Disposition to issuer · Disposed 5,100 · Balance 0 F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration"). |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-30 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2024-06-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-02 · Disposition to issuer · Disposed 150,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.25 · Expires 2025-10-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-02 · Disposition to issuer · Disposed 375,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.00 · Expires 2023-12-30 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-02 · Disposition to issuer · Disposed 25,000 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-01-14 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-03-02 · Disposition to issuer · Disposed 13,200 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.15 · Expires 2031-01-26 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-03-02 · Disposition to issuer · Disposed 31,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2030-01-07 | Direct | 0 |
Reported balance
After 2023-03-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-03-02 · Disposition to issuer · Disposed 27,250 · Balance 0 F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to that certain Agreement and Plan of Merger between the Issuer, Indivior Inc., and Olive Acquisition Subsidiary, Inc., dated as of November 13, 2022 (the "Merger Agreement"), in exchange for a cash payment of $20.00 per share without interest thereon (the "Merger Consideration").
F2: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 37,901 shares of Common Stock upon the acceleration of vesting of restricted stock units in accordance with the Merger Agreement.
F3: 6,667 shares are represented by performance stock units ("PSUs"), the vesting of which accelerated in accordance with the Merger Agreement. Each PSU represents the Reporting Person's right to receive one share of Common Stock of Issuer.
F4: Disposed of pursuant to the Merger Agreement in exchange for the Merger Consideration. The number of shares disposed of reflects 6,667 shares of Common Stock upon the acceleration of vesting of performance stock units in accordance with the Merger Agreement.
F5: The option was cancelled pursuant to the Merger Agreement, in exchange for a cash payment equal to (x) the difference between the Merger Consideration and the per share exercise price of the option, multiplied by (y) the number of disposed option shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 8,641 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · derivative · entry 8 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 8,641 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 26,759 | $13.28 | $355,359.52 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 5 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,882 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $13.22 to $13.50. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 25,000 | $6.00 | $150,000.00 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 4 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 8,641 | $7.25 | $62,647.25 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 25,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · derivative · entry 9 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2023-12-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 16,359 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · derivative · entry 7 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,641 Underlying: Common Stock · 16,359 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 11,834 | $13.54 | $160,232.36 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.47 to $13.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 16:51 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 16,359 | $7.25 | $118,602.75 |
DisclosureSEC source: 0001385508-19-000008 · wf-form4_154698425748836.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 09, 2018 Filed Oct 10, 2018 16:12 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 6,941 | $17.04 | $118,274.64 |
DisclosureSEC source: 0001385508-18-000091 · wf-form4_153920232327206.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 16:12 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 3,059 | $17.33 | $53,012.47 |
DisclosureSEC source: 0001385508-18-000091 · wf-form4_153920232327206.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,416 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 05, 2018 Filed Oct 10, 2018 16:12 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 847 | $18.14 | $15,364.58 |
DisclosureSEC source: 0001385508-18-000091 · wf-form4_153920232327206.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,475 F1 · shares: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 04, 2018 Filed Oct 4, 2018 16:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 4,006 | $18.43 | $73,830.58 |
DisclosureSEC source: 0001385508-18-000086 · wf-form4_153868603565432.xml · nonDerivative · entry 4 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,322 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 03, 2018 Filed Oct 4, 2018 16:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 4,300 | $19.23 | $82,689.00 |
DisclosureSEC source: 0001385508-18-000086 · wf-form4_153868603565432.xml · nonDerivative · entry 3 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,328 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.00 to $19.75. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 16:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionOption · Derivative | 50,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001385508-18-000086 · wf-form4_153868603565432.xml · derivative · entry 5 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 29,297 shares Expires 2025-10-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · shares: Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day closing stock price less exercise price)) divided by the prior day closing stock price. F4 · derivative.underlying_shares: Pursuant to the Stock Option Agreement, the number of shares issued on a cashless basis is determined by the following formula: Number of shares = (number of options times (prior day closing stock price less exercise price)) divided by the prior day closing stock price. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 16:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | SaleCommon Stock | 10,144 | $17.51 | $177,621.44 |
DisclosureSEC source: 0001385508-18-000086 · wf-form4_153868603565432.xml · nonDerivative · entry 2 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,628 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| October 02, 2018 Filed Oct 4, 2018 16:47 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | Exercise / conversionCommon Stock | 29,297 | $7.25 | $212,403.25 |
DisclosureSEC source: 0001385508-18-000086 · wf-form4_153868603565432.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,772 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 10:56 UTC | OPIANT PHARMACEUTICALS, INC. OPNT · Entity 115992 | PurchaseCommon Stock | 3,475 | $6.99 | $24,290.25 |
DisclosureSEC source: 0001144204-17-002837 · v457160_4.xml · nonDerivative · entry 1 CRYSTAL ROGER · CIK 0001656633 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 F1 · price: The price in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.955 to $7.00, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.